Patents by Inventor Stewart T. Cole

Stewart T. Cole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110160193
    Abstract: The present invention relates to novel benzothiazinone derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria. The present invention aims at the generation of new compounds with activity against mycobacteria as potential new tuberculosis drugs to overcome problems concerning resistance and drug intolerance. The solution of the present invention is a compound of formula I wherein R1 to R6 are as defined in the specification.
    Type: Application
    Filed: December 22, 2010
    Publication date: June 30, 2011
    Applicant: Leibniz Institute for Natural Product Research and Infection Biology E.V.
    Inventors: A. Vadim Makarov, Stewart T. Cole, Ute Möllmann
  • Patent number: 7863268
    Abstract: Disclosed are benzothiazin derivatives of formula (I), preparation methods therefore, and treatment methods employing such compounds as antibacterial agents in treating infectious diseases of mammals caused by bacteria, especially diseases like tuberculosis and leprosy caused by mycobacteria: wherein R1, R2, R3, R4, R5, and R6, and other variables enumerated under one or more of R1, R2, R3, R4, R5, and R6 are as defined.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: January 4, 2011
    Assignee: Alere International
    Inventors: A. Vadim Makarov, Stewart T. Cole, Ute Moellmann
  • Publication number: 20090239851
    Abstract: The present invention relates to novel benzothiazin derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria. The present invention aims at the generation of new compounds with activity against mycobacteria as potential new tuberculosis drugs to overcome problems concerning resistance and drug intolerance.
    Type: Application
    Filed: May 24, 2006
    Publication date: September 24, 2009
    Inventors: A. Vadim Makarov, Stewart T. Cole, Ute Möllmann
  • Publication number: 20040121322
    Abstract: The present invention is directed to a method of selection of purified nucleotidic sequences or polynucleotides encoding proteins or part of proteins carrying at least an essential function for the survival or the virulence of mycobacterium species by a comparative genomic analysis of the sequence of the genome of M. tuberculosis aligned on the genome sequence of M. leprae and M. tuberculosis and M. leprae marker polypeptides of nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.
    Type: Application
    Filed: February 22, 2002
    Publication date: June 24, 2004
    Inventor: Stewart T. Cole
  • Publication number: 20030129601
    Abstract: The present invention is directed to a method of selection of purified nucleotidic sequences or polynucleotides encoding proteins or part of proteins carrying at least an essential function for the survival or the virulence of mycobacterium species by a comparative genomic analysis of the sequence of the genome of M. tuberculosis aligned on the genome sequence of M. leprae and M. tuberculosis and M. leprae marker polypeptides of nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.
    Type: Application
    Filed: February 22, 2002
    Publication date: July 10, 2003
    Inventor: Stewart T. Cole
  • Patent number: 5871912
    Abstract: Multi-drug resistant strains of Mycobacterium tuberculosis represent a considerable threat to public health worldwide. Resistance to isoniazid (INH), a key component of anti-tuberculosis regimens, is often associated with loss of catalase activity and virulence. The katG gene, encoding HPI catalase-peroxidase, mediates INH-sensitivity and that the high level resistance encountered clinically may be due to deletions, insertions or point mutations which reduce or eliminate the expression of the catalase gene in the chromosomal region encompassing katG. INH-resistant strains of Mycobacterium tuberculosis are detected by nucleic acid hybridization with a unique nucleic acid sequence or by amplification techniques.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 16, 1999
    Assignee: Institut Pasteur
    Inventors: Beate Heym, Stewart T. Cole, Douglas B. Young, Ying Zhang
  • Patent number: 5633131
    Abstract: Multi-drug resistant strains of Mycobacterium tuberculosis represent a considerable threat to public health worldwide. Resistance to isoniazid (INH), a key component of anti-tuberculosis regimens, is often associated with loss of catalase activity and virulence. The katG gene, encoding HPI catalase-peroxidase, mediates INH-sensitivity and that the high level resistance encountered clinically may be due to deletions, insertions or point mutations which reduce or eliminate the expression of the catalase gene in the chromosomal region encompassing katG. INH-resistant strains of Mycobacterium tuberculosis are detected by nucleic acid hybridization with a unique nucleic acid sequence or by amplification techniques.
    Type: Grant
    Filed: August 14, 1992
    Date of Patent: May 27, 1997
    Assignees: Institut Pasteur, Medical Research Council, Assistance Publique, Universite Paris VI
    Inventors: Beate Heym, Stewart T. Cole, Douglas B. Young, Ying Zhang